US 11,987,584 B2
Heterobicyclic amides as inhibitors of CD38
Laurie B. Schenkel, Cambridge, MA (US); Melissa Marie Vasbinder, Cambridge, MA (US); Kevin Wayne Kuntz, Cambridge, MA (US); Nicholas Robert Perl, Cambridge, MA (US); and Jennifer Downing, Cambridge, MA (US)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim (DE)
Filed by Ribon Therapeutics, Inc., Cambridge, MA (US)
Filed on Dec. 5, 2022, as Appl. No. 18/074,746.
Application 18/074,746 is a continuation of application No. 16/942,857, filed on Jul. 30, 2020, granted, now 11,535,621.
Claims priority of provisional application 63/034,750, filed on Jun. 4, 2020.
Claims priority of provisional application 62/951,604, filed on Dec. 20, 2019.
Claims priority of provisional application 62/880,923, filed on Jul. 31, 2019.
Prior Publication US 2023/0312586 A1, Oct. 5, 2023
Int. Cl. C07D 487/04 (2006.01); A61P 35/00 (2006.01); C07D 403/10 (2006.01); C07D 417/10 (2006.01); C07D 471/04 (2006.01); C07D 473/32 (2006.01); C07D 495/04 (2006.01); C07D 513/04 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 35/00 (2018.01); C07D 403/10 (2013.01); C07D 417/10 (2013.01); C07D 471/04 (2013.01); C07D 473/32 (2013.01); C07D 495/04 (2013.01); C07D 513/04 (2013.01)] 22 Claims
 
1. A method of inhibiting a function of CD38 comprising contacting a compound which is selected from:
2-(1H-Imidazol-1-yl)-N-((1r,4r)-4-(2-methoxyethoxy)cyclohexyl)-5H-pyrrolo[3,2-d]pyrimidine-4-carboxamide,
5-(1H-imidazol-1-yl)-N-((1r,4r)-4-((2,2,2-trifluoroethyl)amino)cyclohexyl)-1H-pyrazolo[3,4-c]pyridine-7-carboxamide,
N-((1r,4r)-4-(2-hydroxypropan-2-yl)cyclohexyl)-5-(1H-imidazol-1-yl)-1H-pyrazolo[4,3-d]pyrimidine-7-carboxamide,
5-(1H-imidazol-1-yl)-N-((1r,4r)-4-(3,3,3-trifluoropropyl)amino)cyclohexyl)-1H-pyrazolo[3,4-c]pyridine-7-carboxamide,
5-(1H-imidazol-1-yl)-N-((1r,4r)-4-((2,2,2-trifluoroethyl)amino)cyclohexyl)-1H-pyrazolo[4,3-d]pyrimidine-7-carboxamide,
N-((1r,4r)-4-(2,2-difluoropropyl)amino)cyclohexyl)-5-(1H-imidazol-1-yl)-1H-pyrazolo[3,4-c]pyridine-7-carboxamide, and
N-((1r,4r)-4-(2,2-difluoroethyl)amino)cyclohexyl)-5-(1H-imidazol-1-yl)-1H-pyrazolo[3,4-c]pyridine-7-carboxamide,
or a pharmaceutically acceptable salt thereof, with the CD38.